Crystal Research Associates has issued a 17-page Company Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Snapshot of GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing innovative vaccines for some of the world’s most serious infectious diseases and therapies for solid tumor cancers. The Company’s flagship program, GEO-CM04S1, is a next-generation COVID-19 vaccine. GeoVax recently secured a BARDA-funded contract to conduct a 10,000-participant Phase 2b clinical trial to assess the efficacy of GEO-CM04S1 compared to an approved COVID-19 vaccine. Additionally, GEO-CM04S1 is currently being tested in three Phase 2 clinical trials: (1) as a primary vaccine for immunocompromised patients, including those with hematologic cancers, who may not benefit sufficiently from existing COVID-19 vaccines, (2) as a booster for patients with chronic lymphocytic leukemia (CLL), and (3) as a more robust, durable COVID-19 booster for healthy individuals who have previously received mRNA vaccines. In the oncology field, GeoVax’s leading program is the evaluation of Gedeptin®, a novel oncolytic gene-directed therapy for solid tumors, currently in a multicenter Phase 1/2 trial targeting advanced head and neck cancers. GeoVax also has a solid intellectual property portfolio, holding global rights to its technologies and product candidates. The Company’s leadership team has a proven track record of creating significant value across multiple life science companies over the past few decades.
Key Points
- On August 6, 2024, GeoVax announced second quarter 2024 financial results and provided a corporate update. Net loss for the three months ended June 30, 2024 was $5,064,042, or $1.99 per share versus $5,927,620, or $3.79 per share, for the comparable period in 2023.
- GeoVax has made significant strides during the first half of 2024, highlighted by the recent receipt of the BARDA Project NextGen award to evaluate GEO-CM04S1, the Company's next-generation, dual-antigen COVID-19 vaccine. In addition, GeoVax has partnered with Allucent, a global CRO, to initiate the trial and advance GEO-CM04S1 into the BARDA-funded 10,000-patient Phase 2b clinical study. With over $350 million secured for the trial, this U.S. government recognition not only validates GeoVax's clinical strategy but also provides the necessary resources to accelerate its development.
- GEO-CM04S1 has demonstrated potent, broadly reactive, and long-lasting antibody and T cell immune responses in individuals with both healthy and compromised immune systems. Given the increasing understanding that robust T cell responses are crucial for antibody recall and protection against severe disease and hospitalization, GeoVax believes that GEO-CM04S1 stands-out as a next-generation COVID-19 vaccine with the ability to greatly enhance patient care.
- With support from an oncology clinical advisory committee and following a thorough review of Gedeptin’s safety and efficacy data, GeoVax is poised to advance an expanded Phase 2 clinical trial evaluating Gedeptin in patients with first-recurrence head and neck cancer.
- GeoVax continues to strengthen its global intellectual property position, with over 115 granted or pending patent applications spread over twenty-four patent families.
- The Company anticipates forming business partnerships and collaborations to support the global development, commercialization, and distribution of its products.
- GeoVax reported cash balances of $1,561,712 at June 30, 2024 versus $6,452,589 at December 31, 2023.
*******************************************
Visit our Corporate Profile and Key Points pages
for the latest research on GeoVax Labs, Inc.
*******************************************